Testing VT3989 for certain advanced cancers
Treatments studied
Part of Cancer clinical trials.
This early-stage trial tests VT3989 in people with specific advanced (metastatic or unresectable) cancers. It may help shrink tumors or slow cancer growth in patients who fit the genetic or diagnosis-specific requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: malignant mesothelioma or NSCLC with specific EGFR changes (exon 19 deletion or exon 21 L858R)
- Your cancer is advanced (metastatic or inoperable/recurrent) and is considered measurable by the trial’s scan rules
- You have not had the specific prior treatments required for your cancer type (or you meet the allowed prior-treatment options listed for your cohort)
- Your general health status is good enough (ECOG 0–1) and key organs are working well (liver, kidneys, and blood counts)
- You do not have active brain metastases or a history of leptomeningeal spread
- You are not pregnant or breastfeeding, and you have no conditions that bar treatment (like uncontrolled infections, known HIV/Hepatitis B or C, or certain heart rhythm problems)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
This trial tests a new drug (called a TEAD inhibitor) against two standard chemotherapy drugs (gemcitabine and vinorelbine) for people with advanced epithelioid mesothelioma who have already had chemotherapy and immunotherapy. The study aims to see if the new drug works better than the standard options.
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
This trial tests two experimental drugs given together to treat advanced solid tumors that have not responded to previous treatments. The goal is to see if the combination helps shrink or control the cancer, and the study is for people who are otherwise in fairly good health.
This trial tests new experimental cancer treatments and technologies for people with rare or hard-to-treat tumors. It aims to find tailored therapies that may work better for your specific cancer. You will be asked to provide a tumor sample for testing, and the trial team will guide you through the process.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.